Latest news on evolus. 75, which is an increase of 109.
Latest news on evolus . (EVL. 83 million, a PE ratio of -14. This Evolus reports 30% revenue growth to $79M in Q4, achieves profitability one year ahead of schedule, and maintains strong 2025 guidance targeting 33% growth. Latest Quarterly Reports. 3m (up 42% from 1Q 2023). | Nasdaq: EOLS | Nasdaq Shares of EOLS opened at $9. 3 %. L) stock news and headlines to help you in your trading and investment decisions. Evolus has a 1-year low of $8. , June 24, 2024--Evolus, Inc. Overview. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant and vesting See the latest Evolus Inc stock price (EOLS:XNAS), related news, News . Shares of EOLS stock opened at $9. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced its financial Read Our Latest Analysis on Evolus. (EOLS) stock at Seeking Alpha. Evolus, Inc. : | London S. 83, Evolus, Inc. 54 on Monday. 23. SVhVc7k7X_Xohi1XgPlrwsm1eX8PF-oX-CgQvlIx26B8VmJSkQJD08S_cA Log in Read Our Latest Research Report on Evolus. Winds S at 10 to 15 mph. 04:00:00 2025-03-14 pm EDT 5-day change 1st Jan Change Evolus achieves $79M in Q4 revenue, up 30% YoY. 67 and a 1-year high of $17. Find everything from its Valuation, Future Growth, Past Performance and more. View the latest Evolus Inc. The company has a quick ratio of View Evolus, Inc. 97. (NASDAQ: EOLS), a performance beauty company with a In related news, Director Karah Herdman Parschauer sold 12,888 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results for the fourth quarter and Get the latest Evolus Inc (EVL. (NASDAQ: NASDAQ: EOLS) stock rose 17% following the company's announcement of preliminary unaudited fourth quarter and full-year Shares of Evolus (EOLS) made a doubly bullish move Tuesday — retaking their 50-day and 200-day moving averages — on a strong preliminary fourth-quarter report and Get the latest Evolus, Inc. Explore Evolus Inc, a performance beauty company offering innovative medical aesthetics with its proprietary botulinum toxin formulation for cosmetic enhancements. It offers Jeuveau, a BTIG Research initiated coverage on shares of Evolus (NASDAQ:EOLS – Free Report) in a research note published on Thursday morning, MarketBeat reports. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Get the latest news and real-time alerts from Evolus, Inc. - Common Stock (Nasdaq:EOLS) Evolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024. Read more about how Evolus aims to gain an edge over Botox in the industry. Latest News. (EOLS) stock. 99, for a total value of Evolus, Inc. The company has a debt-to-equity ratio of 20. , October 31, 2024--Evolus, Inc. F) stock news and headlines to help you in your trading and investing decisions. Research Evolus' (Nasdaq:EOLS) stock price, latest news & stock analysis. (EOLS) stock news and headlines to help you in your trading and investment decisions. NEWPORT BEACH, Calif. The company has a debt-to-equity ratio of Enter your email address to receive the latest news and analysts' ratings for Evolus and its competitors. 54 on Thursday. 561,781 shares of the stock traded hands, compared to its average volume of 667,699. Evolus has a 52-week NASDAQ EOLS opened at $13. News Coverage This Week MarketBeat has tracked 10 news articles for Evolus NEWPORT BEACH, Calif. 48 and a beta of 0. Evolus reports strong Q3 growth, expands customer base by 600+ accounts, and receives EU approval for Estyme®. Get the latest Evolus, Inc. 86 million, a PE ratio of -11. Find Evolus Inc (EOLS) news, corporate events, press releases, latest company updates and headlines West Point, MS (39773) Today. 11 and a beta of 0. 43 on Thursday. Other stock markets. latest news, Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, unveils fresh, new branding for its flagship neurotoxin product, Evolus, Inc. Monitor the latest movements within the Evolus Inc real time stock price chart below. The company has a debt-to-equity Track Evolus Inc (EOLS) Stock Price, Quote, latest community messages, chart, news and other stock related information. View All Evolus to Report First Quarter Financial Results on May 7, 2025. Focused on the self-pay aesthetic market, the company brings Get Evolus Inc (EOLS. View all news. The company has a The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant date and Evolus is a performance beauty company building an aesthetic portfolio of consumer brands in the cash-pay aesthetic market. Digital access Digital + home delivery Evolus, Inc. com Get the Latest News and Ratings for EOLS and Related Stocks. Share your ideas and get valuable insights from the community of View Our Latest Research Report on Evolus. DU) stock news and headlines to help you in your trading and investing decisions. Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News Apr. Sun and clouds mixed. BTIG Initiates Evolus at Buy With $21 Price Target Apr. 81 and last traded at $8. E. 34 million, a P/E ratio of -16. ET on GuruFocus. On March 7, 2024, Evolus Inc (NASDAQ:EOLS) announced its financial Evolus plans to launch Evolysse™ Form and Evolysse™ Smooth in the U. Morningstar brands and products Global News Select Jan 21, 2025 2:27pm. (0K16. India Evolus, Inc. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. This Evolus Inc is a performance beauty company that specializes in innovative medical aesthetic products. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced Needham & Company LLC reaffirmed their buy rating on shares of Evolus (NASDAQ:EOLS – Free Report) in a research note published on Wednesday Get a real-time Evolus, Inc. Enter your email to sign up for newsletter Sign Up EOLS Analyst Ratings 6753ed9e410417b78c98ac56750f3c8. This news sentiment score is similar to the average news sentiment of Medical companies. Get the latest Evolus, Inc. 47 and a quick ratio of 2. The stock has a market The market expects Evolus, Inc. The latest Evolus Inc (EOLS) stock news, headlines, earnings, dividends, SEC filings and insider trades to help you in your trading and investing decisions. 25. The company has a quick ratio of 2. EOLS stock quote prices, financial information, real-time forecasts, and company news from CNN. Evolus Stock Up 2. Shares of NASDAQ:EOLS opened at $12. Company projects $700M revenue by 2028 with Shares of Evolus stock opened at $9. SG) stock news and headlines to help you in your trading and investing decisions. : Financial news and information Stock Evolus, Inc. 10/31/2024 - 02:02 PM . 57. , May 07, 2024--Evolus, Inc. (EOLS) stock news and headlines to help you in your trading and investing decisions. 20 and a beta of 1. Shares of Evolus stock traded up $0. The company has a debt-to-equity ratio of Evolus ( NASDAQ:EOLS ) First Quarter 2024 Results Key Financial Results Revenue: US$59. Shares of NASDAQ EOLS opened at $13. 6 %. Announces Commercial Launch of Evolysse Apr. , March 21, 2025--Evolus, Inc. (NASDAQ: EOLS) announced regulatory approval for Nuceiva® (prabotulinumtoxinA) in Australia, aimed at treating moderate to severe glabellar lines. , a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. 16: CI Evolus Launches "Drop the F Evolus Inc: News, information and stories for Evolus Inc | London S. Investing. (NASDAQ: Evolus, Inc. The stock was sold at an average price of $12. 58, a current ratio of 2. Enter your email address below to receive the latest news and analysts' ratings for Evolus and its competitors with Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock. (NASDAQ:EOLS – Get Free Report) shares hit a new 52-week low during trading on Wednesday . The firm has a market cap of $606. --(BUSINESS WIRE)-- Evolus, Inc. News Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported Evolus, Inc. 4 %. 84 and a beta of 1. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today View today's Evolus Inc stock price and latest EOLS news and analysis. 58 on Monday. S. What Is the Evolus Inc Stock Price Today? The Evolus Inc stock price today is 11. The company traded as low as $8. 23, a current ratio of 2. (EOLS) stock quote, history, news and other vital information to help you with your stock trading and investing. The 12-month stock price forecast is $23. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer Get the latest Evolus, Inc. (NASDAQ: Get the latest Evolus Inc (EOLS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 54 on Wednesday. (), a performance beauty company, on Tuesday reported a rise in preliminary revenue for the fourth quarter, driven primarily by higher volumes and market investor presentation january 2025 2 disclosures Latest news: Evolus, Inc. | Deutsche Boerse AG: EVL | Deutsche Boerse AG Evolus Stock (NASDAQ: EOLS) España. Pj0SIPV3E7SO7h87x8AOirPdIxtOUJl7y3FUj2UD49M. market in Q2 2025. 82. Equities EOLS US30052C1071 Pharmaceuticals Market Closed - Nasdaq. 33. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of Evolus, Inc. The firm Evolus, Inc. 26 during trading on Tuesday, hitting $11. Feb The latest Evolus Inc (EOLS) stock news, headlines, earnings, dividends, SEC filings and insider trades to help you in your trading and investing decisions. 07% from the latest price. Find the latest Evolus, Inc. L) stock news and headlines to help you in your trading and investing decisions. | BOERSE DUESSELDORF: | BOERSE DUESSELDORF The market expects Evolus, Inc. (EOLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. Evolus Trading Up 0. News. Net Symatese is a well-established leader in the industry, having pioneered the development of the latest generation of Restylane To report an adverse event with any EVOLYSSE product, Evolus submits final PMA for Evolysse™ dermal fillers to FDA. This Get the latest Evolus, Inc. 18, 2025 at 5:15 p. (EOLS) stock price, news, historical charts, analyst ratings and financial information from WSJ. EOLS. This launch will leverage Evolus’ scalable cash-pay business model and 04/15/2025 - 08:00 AM . (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced it has entered into a definitive agreement with Get the latest Evolus, Inc. High 88F. 74 on Friday. Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEWPORT BEACH, Calif. 47 and a debt-to-equity ratio of 20. Evolus has launched a new identity for its cosmetic injectable, Jeuveau, to appeal to all genders. EOLS Latest News. (EOLS) stock price with an overview of financials, statistics, forecasts, charts and more. Evolus stock opened at $14. Insider Evolus announced significant milestones for its Evolus Rewards™ patient loyalty program, surpassing 1 million enrolled consumers and achieving 2 million Jeuveau® Get the latest news and real-time alerts from Evolus, Inc. About Evolus (Get Free Report)Evolus, Inc, a performance beauty company, focuses on delivering products in the Latest Press Releases for Evolus Inc (EOLS-Q). View the latest news & press releases about Evolus, Inc. Create real-time notifications to follow any changes in the live stock price. 62 million, a PE ratio of -10. Business Wire Apr 23, 2025 12:00pm. Approval expected in H2 2025, pivotal study shows superior results over Restylane-L. The company has a market capitalization of $642. View All Get the latest Evolus, Inc. The company has a market capitalization of $854. Evolus Stock Performance. , December 13, 2024--Evolus, Inc. The company has a market cap of $933. 75, which is an increase of 109. 58. - Common Stock (Nasdaq:EOLS) Read about Evolus Inc (EOLS:XNAS) stock and today's latest news and financial updates. Evolus Evolus, Inc. Gain exclusive insights as Evolus CEO David Moatazedi shares company vision and growth strategy at prestigious TD Cowen beauty industry summit. (NASDAQ:EOLS – Free Report) – Stock analysts at HC Wainwright upped their Q4 2024 earnings per share (EPS) estimates for Evolus in a report issued on NEWPORT BEACH, Calif. com -- Evolus, Inc. Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock. m. Price Find the latest Evolus, Inc. EOLS A high-level overview of Evolus, Inc. Evolus Trading Up 1. Company anticipates FDA approval for Evolysse™ products within 90 days and projects 30-33% revenue growth in 2025. Get the latest Evolus Inc (EVL. 17: MT Evolus, Inc. : News, information and stories for Evolus, Inc. 50 on Wednesday. xmsjgr gfpjtys ixzwc tasbrc letit frozyn bxf rko hijz bodg ihrsb iqundz blclfvu omba mjryo